Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. | Bicycle Therapeutics is ...

R oche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

Genentech's Portal study shows Susvimo maintains vision and retinal drying in wet AMD patients over five years with biannual ...

Genentech, a member of Roche (RHHBY), announced that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s ...

Washington has long failed to come up with a solution for rising drug prices that addresses the concerns of drugmakers, ...

About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from its CD20xCD3 T-cell engaging bispecific antibo ...

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get ...

Genentech has held its pre-eminent place for decades, rolling out successive waves of firsts in drug development. The company and its collaborators at City of Hope national medical center used ...

Genentech will also move its anti-CD11a monoclonal antibody (developed in collaboration with Xoma, Berkeley, CA) into phase III trials as a treatment for psoriasis.